> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Open to Single Phase 3 for Netherton Syndrome Drug
- URL: https://www.fdaweb.com/fda-open-to-single-phase-3-for-netherton-syndrome-drug/
- Published: 2026-03-25T12:00:00.000Z
- Updated: 2026-09-14T13:36:09.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5160873

Quoin Pharmaceuticals says FDA has signaled openness to a streamlined development path for its rare disease candidate QRX003, indicating that a single Phase 3 trial could be sufficient to support approval in Netherton Syndrome. The feedback came out of a recent Type C meeting, where regulators also suggested flexibility on trial design, including the possibility of skipping a traditional placebo- or vehicle-controlled study in favor of alternative approaches such as randomized withdrawal or delayed-start designs, according to the company.

For a rare dermatologic condition like Netherton syndrome, where patient populations are small and disease burden is high, that kind of regulatory flexibility could significantly reduce both development timelines and trial complexity. Quoin says it had previously been planning for two Phase 3 studies. The shift to a potential single pivotal trial, combined with a non-traditional design, could materially accelerate the program.

The company says it remains on track to begin its Phase 3 study and complete enrollment this year, with a potential NDA filing in 2027\. Ahead of that, Quoin plans to submit data from its ongoing mid-stage and investigator-led pediatric studies and seek further FDA alignment on the pivotal trial design.

QRX003 is being developed as a potential first-approved therapy for Netherton syndrome, a rare genetic disorder characterized by severe skin barrier defects and chronic inflammation. There are currently no FDA-approved treatments for the condition, according to the company.